Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 overexpression
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR2 fusion (24)
FGFR2-BICC1 fusion (8)
FGFR2-AFF4 fusion (5)
FGFR2-CCDC6 fusion (3)
FGFR2-KIAA1217 fusion (2)
FGFR2-NRAP fusion (2)
FGFR2-POC1B fusion (2)
FGFR2-SORBS1 fusion (2)
FGFR2-TACC3 fusion (2)
FGFR2-ZMYM4 fusion (2)
FGFR2-AHCYL1 fusion (1)
FGFR2-ARHGAP24 fusion (1)
FGFR2-CASP7 fusion (1)
FGFR2-CLIP1 fusion (1)
FGFR2-ERC1 fusion (1)
FGFR2-INA fusion (1)
FGFR2-OFD1 fusion (1)
FGFR2-OGA fusion (1)
FGFR2-OPTN fusion (1)
TACC2-FGFR2 fusion (1)
FGFR2 fusion (24)
FGFR2-BICC1 fusion (8)
FGFR2-AFF4 fusion (5)
FGFR2-CCDC6 fusion (3)
FGFR2-KIAA1217 fusion (2)
FGFR2-NRAP fusion (2)
FGFR2-POC1B fusion (2)
FGFR2-SORBS1 fusion (2)
FGFR2-TACC3 fusion (2)
FGFR2-ZMYM4 fusion (2)
FGFR2-AHCYL1 fusion (1)
FGFR2-ARHGAP24 fusion (1)
FGFR2-CASP7 fusion (1)
FGFR2-CLIP1 fusion (1)
FGFR2-ERC1 fusion (1)
FGFR2-INA fusion (1)
FGFR2-OFD1 fusion (1)
FGFR2-OGA fusion (1)
FGFR2-OPTN fusion (1)
TACC2-FGFR2 fusion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2 overexpression
Gastric Cancer
FGFR2 overexpression
Gastric Cancer
AMG 552
Sensitive: C2 – Inclusion Criteria
AMG 552
Sensitive
:
C2
AMG 552
Sensitive: C2 – Inclusion Criteria
AMG 552
Sensitive
:
C2
FGFR2 overexpression
Lung Non-Small Cell Squamous Cancer
FGFR2 overexpression
Lung Non-Small Cell Squamous Cancer
BAY 1163877
Resistant: C3 – Early Trials
BAY 1163877
Resistant
:
C3
BAY 1163877
Resistant: C3 – Early Trials
BAY 1163877
Resistant
:
C3
FGFR2 overexpression
Breast Cancer
FGFR2 overexpression
Breast Cancer
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
FGFR2 overexpression
Hormone Receptor Positive Breast Cancer
FGFR2 overexpression
Hormone Receptor Positive Breast Cancer
palbociclib + BAY 1163877
Sensitive: C3 – Early Trials
palbociclib + BAY 1163877
Sensitive
:
C3
palbociclib + BAY 1163877
Sensitive: C3 – Early Trials
palbociclib + BAY 1163877
Sensitive
:
C3
FGFR2 overexpression
Gastrointestinal Cancer
FGFR2 overexpression
Gastrointestinal Cancer
ARQ 087
Sensitive: D – Preclinical
ARQ 087
Sensitive
:
D
ARQ 087
Sensitive: D – Preclinical
ARQ 087
Sensitive
:
D
FGFR2 overexpression
Breast Cancer
FGFR2 overexpression
Breast Cancer
ponatinib
Sensitive: D – Preclinical
ponatinib
Sensitive
:
D
ponatinib
Sensitive: D – Preclinical
ponatinib
Sensitive
:
D
FGFR2 overexpression
Breast Cancer
FGFR2 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
FGFR2 overexpression
Cholangiocarcinoma
FGFR2 overexpression
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login